Bristol-Myers Squibb (BMY) 8-K Regulation FD Disclosure

Exhibit 99.1

   Investor Event  November 16, 2021   

   Forward Looking Statement and Non-GAAP Financial Information  2  This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the Company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available on the SEC’s website, on the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.This presentation includes certain non-generally accepted accounting principles (GAAP) financial measures that we use to describe our company’s performance.  The non-GAAP information presented provides investors with additional useful information but should not be considered in isolation or as substitutes for the related GAAP measures.  Moreover, other companies may define non-GAAP measures differently, which limits the usefulness of these measures for comparisons with such other companies.  We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.  An explanation of these non-GAAP financial measures and a reconciliation to the most directly comparable GAAP financial measure are available on our website at bms.com/investors. Also note that a reconciliation of certain forward-looking statements, however, is not provided due to no reasonably accessible or reliable comparable GAAP measures for such statements and the inherent difficulty in forecasting and quantifying such statements that are necessary for such reconciliation. 

 Today’s Agenda  3  Rupert Vessey  Samit Hirawat  Chris Boerner  David Elkins    Giovanni Caforio  Strategic Overview  Innovation Engine & Early Pipeline  Late-Stage Pipeline Update  Commercial Opportunities  Financial Overview  BREAK (10 min)  Giovanni Caforio  Closing, Q&A  Conclusion, lunch reception  12:00 pm 

 Giovanni CaforioBoard Chair and Chief Executive Officer  Strategic Overview 

 A differentiated biopharma company focused on innovative medicines for patients with cancer and other serious diseases  BEST OF BIOTECHBEST OF PHARMA  Leading scientific innovationCollaborating at center of the biotech ecosystemLeveraging global scale and agilityDriven by the best people  5  Our strategic foundation 

   Diabetes business divested, e.g.  Creating our biopharma company  Focusing on specialty medicines  Deepening our innovation engine& long-term growth drivers  BioPharma Strategyintroduced  2013  2007  2008  2009  2019  2020        2021  2017  2012  2010  2011  2014  2015  2016  2018                            Continued execution of biopharma strategy  6  New product portfolio launches      LOE  LOE  LOE  LOE  acquisition  divestiture  Portfolio transformation enabled by strong track record of commercial execution 

 From 11 to 22 Phase 3 & registrational expansion opportunities  Deepening our innovation engine since 2019  7  Deeper pipeline   Expanded research platforms  Industry leading Protein Homeostasis capability Expanding Cell Therapy platforms  Broader external partnership network  Currently >300  From 29 to 64 Phase 1 & 2 assets 

         Well positioned with a diverse portfolio of leading medicines  8  Leading Products across Four Therapeutic Areas  Robust Early-stage Pipeline**  Across leading drug discovery platforms:Small moleculesProtein homeostasisBiologicsCell therapy  **Phase I / II Assets  Financial strength enabling continued investment for growth  Solid Tumor Oncology  deucravacitinib*   mavacamten*  + Expansion opportunities across multiple assets  50+ assets  Hematology  Cardiovascular  Immunology    Deep & Broad Late-stage Pipeline   New Product Portfolio  rela+nivo FDC*  milvexian  BCMA TCE  cendakimab  bempeg  iberdomide  FRa ADC  CC-92480  * Anticipated launches 

     Our Commitment as a sustainable organization    Embracing environmental stewardship  9  Experienced & diverse Board Board oversight of strategy& key enterprise risks60% female & ethnically diverse directorsShareholder rightsRegular shareholder engagementProxy access Special meeting right (15%)  Environment  Governance  Social  Key Priorities  Concrete Commitments  2021  ≥ 25% new clinical trial sites in diverse metro areas  2022  Gender parity at executive level2X representation for Black/African American & Hispanic/Latino executives  2025  $1B spend with diverse suppliers    2024  Science-based emissions reduction targets established  2030  100% renewable electricity  2040  Net neutral GHG100% EV fleet100% equitable water useZero waste to landfill  Maintaining highest ethics, integrity & complianceUpholding Board oversight & accountability  Promoting product quality & safetyCultivating diversity, equity & inclusionEnsuring health equity, patient access & innovation 

   Confidence in our ability to address future key LOE exposures  10  Mid to late stage Pipeline  Early-Stage Pipeline  Financial strength  New Product Portfolio  1H Decade  Multiple drivers of growth to more than offset LOE headwinds  2H Decade    $25B+ NRA revenue potential  50+ assets  $45 - $50B free cash flow 2021-2023  milvexian  BCMA TCE  cendakimab  bempeg  iberdomide  FRa ADC  CC-92480  NRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approvalFinancial projections may contain non promoted sales, BMS promotes only according to label 

   ($12B – $14B)  +$8B – $10B  +$10B – $13B  2020 Revenues  LOE Brands  In-Line Brands  Primarily I-O & Eliquis  2025 Revenues  New Product Portfolio  Growth 2020-2025Low to mid-single digit revenue CAGR*  2020-2025 revenue growth:Continuing Business offsets LOEs  11  LOE Brands = Revlimid, Pomalyst, Sprycel, and Abraxane  Not for Product Promotional Use    Continuing Business  Financial projections may contain non promoted sales, BMS promotes only according to label    *At constant exchange rates – Non-GAAP, on a risk-adjusted basis - There is no reliable or reasonable estimable comparable GAAP metric for this non-GAAP forward-looking information 

 Revlimid, Eliquis & I-O  Opportunity for a more diversified portfolio in 2025  12  Not for Product Promotional Use  New Product Portfolio  All Other  Eliquis & I-O      New Product Portfolioexpected to represent ~25% of total company revenue expected in 2025, with continued growth expectedReduced concentration of top brands from ~70% in 2020 to ~50% in 2025; trend expected to continue    Total Company Revenue Composition    New Product Portfolio = Abecma, Breyanzi, Inrebic, Onureg, Reblozyl, Zeposia, deucravacitinib, mavacamten, rela + nivo FDC 

   New Product Portfolio has significant growth potential  deucravacitinib  $3B+  $4B+  Note: Non-risk adjusted sales subject to positive registrational trials and health authority approval  $1B+  mavacamten  rela+nivo FDC  Broad New Product Portfolio with $25B+non-risk adjusted revenue potential in 2029  13 

   Solid Tumor Onc $80B+    Lung $25B+  CRC $7B+  Breast $21B+  Prostate $10B+  Ovarian $2B+  Renal $7B+  Melanoma $7B+  GI $1B+  H&N $2B+  Liver $1B+    Immunology $75B+    RA $28B+  Psoriasis $20B+  PsA $4B+  Ank. Spond. $1B+  Lupus $1B+  Atopic Derm $4B+  UC $6B+  Crohn’s $13B+    Hematology $40B+    MM $20B+  NHL $11B+  MDS $1B+  AML $1B+  CLL $6B+          Broad pipeline addresses diseases with significant commercial potential  Mid to late-stage pipeline  Early-stage pipeline  milvexian  BCMA TCE  cendakimab  bempeg  iberdomide  FRa ADC  CC-92480  50+ assets  Focused in disease areas with large and growing commercial potential  Cardiovascular $20B+    HF $3B+  Thrombosis $19B+  Source: EvaluatePharma 2020 estimates   14 

 Current focus: Emerging science-based in-licensing opportunitiesSmall & mid-sized bolt-on opportunities to strengthen innovation engine & long-term growth profile  Consistent criteria for sourcing external innovation  Business Development remains a top priority  15  Strategically AlignedScientifically SoundFinancially Attractive  Not for Product Promotional Use  OncologyHematologyImmunology  Focusedon therapeutic areas of interest  CardiovascularNeurology 

   New Product Portfolio and pipeline provide multiple pathways to growth from 2025 to 2029    New product portfolio and pipeline products will continue to provide revenue replacement power, offsetting Eliquis and I-O LOEs        Additional optionality from disciplined Business Development  Delivery of late-stage pipelineCombination of new products & high-value expansion opportunities:Reblozyl LCMdeucravacitinib LCMmavacamten LCMrelatlimab LCMmilvexianiberdomide   2025 Revenues  LOE Brands  2029 Revenues  Additional growth from New Product Portfolio  Advancing robust pipeline  Diverse, growing New Product Portfolio        Growth 2025-2029  16 

 Critical 2022 & 2023 deliverables to unlock value of New Product Portfolio  Enable expansion forReblozyl through successful1L MDS COMMANDS trial  17  deucravacitinib  mavacamten  Deliver successful launch of mavacamten over the next year  Establish deucravacitinib as oralof choice in Psoriasis  Establish broad access for Zeposia in UC  Build industry-leading cell therapy franchise, anchored on Breyanzi 

 What we will cover with you today  18  Provide insight to our innovation engine  Rupert Vessey  Samit Hirawat  Chris Boerner  David Elkins  Review ourmid & late-stage pipeline  Discuss the building blocks of growth  Review our financial strength & approach to capital allocation   

 Innovation Engine & Early Pipeline  Rupert Vessey,MA, BM, BCh, FRCP, DPhil President, Research & Early Development  

 R&D Strategic Foundation  An innovation company developing first-in-class & best-in-class medicines addressing significant unmet need  20  External Partnerships  Portfolio Execution  Talent  Key Enablers of Our Success  Innovative R&D Platforms  Digital Innovation 

 An Integrated Approach to Research and Development  21      Global Drug DevelopmentMaximize innovation and productivity for late stage and LCM opportunities  Research & Early DevelopmentDrive innovation and bring forward next generation assets                  

 Differentiated and Diversified Portfolio Grown through Internal R&D and BD  22          Distribution of clinical pipeline (2019 to 2021) # of assets  Diversifying portfolio across TAs  Rich early and mid-stage pipeline  Modality agnostic approach  5  2019  40  2021  4  3  86  Neuroscience  Cardiovascular  Hematology  Fibrosis  Immunology  Oncology  86  11  2021  2019  Ph1, Ph2  Ph3, LCM  86  40  2021  2019  Biologic  Small Molecule  Cell Therapy  4  40 

       Industry Leading Drug Discovery Platforms  23  Complex Biotherapeutics  Small Molecule Drug Discovery  Protein Homeostasis   Cell Therapy  Screening2.5MM Cmpds50K CelMods  Hit ValidationExploratory SAR CryoEM  Lead OptimizationMedchem - RadiochemML - Cheminformatics        New Targets  Drug Candidates  Cro Network            CAR T technology: recognizes proteinson the surface of cancer cells  TCR technology: recognizes intracellular tumor-specific proteins  CAR  TCR  Probodies  Immune Cell Engagers  Bi-Specifics  Site Specifics ADCs 

 Novel Assets Advancing from our Protein Homeostasis Platform  24    CELMoD  LDD  Novel  Target  Cereblon    Target  Ligase      Target  ?    Molecular Glue  Heterobifunctional  Intrinsic Degrader  1  2  3  Modalities  Asset  Indication  Phase  iberdomideA/I* CELMoD  MM  Late Development  CC-92480A/I* CELMoD  MM  Late Development  CC-90009GSPT1 CELMoD  AML  Early Development  CC-99282A/I* CELMoD  Lymphoma  Early Development  CK1α CELMoD  AML  Early Development  AR-LDD  Prostate Cancer  Early Development  2 Novel LDD5 Novel CELMoD  Heme-Onc, Inflammation  Full Discovery  * Aiolos/Ikaros 

 Broad Investment in Next Generation Cell Therapies  25  Engineered TCR T Cells for Solid Tumors  CAR T Armed Payload  Recognizes intracellular targets  Overcoming tumor microenvironment resistance  Healthy donors  Patients  Allogeneic CAR T Cells  Off the shelf alternative  Enabled through strategic partnering  Dual Antigen Targeting CAR Ts  Mitigating antigen loss 

 Immune Cell Engager Molecules are Complementary Modalities to Cellular Therapy  26  Current Portfolio (public)  Bispecific Antibodies: Direct host immune cells (T or NK) to recognize & attack tumor cells    Indication  Asset  Disc  Pre-clinical  Ph1  AML  CD33 NKE          AML target NKE          AML target NKE        Lymphoma / CLL  BCM target NKE           BCMA TCE        Myeloma  BCMA NKE          BCMA TCE        Solid Tumor  Solid tumor target TCE          ST target NKE          ST target NKE        Inflammation/neuroscience   NS target NKE                              (CC-93269) 

 >85Active Collaborations  4INDs Filed 2021  9Licenses Optioned 2021  Internal R&ED Strengths are Amplified through Active External Partnerships  27                      Neuroscience  Immuno- Oncology & Cell Therapy  Oncogenesis  Tumor Micro- Environment  Mechanisms of Cancer Resistance  Cross-Therapeutic  Informatics & Predictive Sciences  Discovery Biothera-peutics  Small Molecule Drug Discovery  Inflammation, CV & Fibrosis  EXEMPLAR  MMPACT 

 Rapidly Advancing Neuroscience Pipeline Built through External Partner Network  28  By end of 2023, five assets will have completed Phase 1 and two assets will have Phase 1 ongoing  Machine learning  Protein Homeostasis  Protein Clearance  RNA Splicing  Remyelination and Repair  Neuroinflammation Zeposia approved US and EU 2020  Mitophagy  Endocannabinoid enhancer IND 2020: FIH June 2020  CC-97489  Multiple SclerosisNeuroinflammation 

   Opportunities for Visibility and Guidance  Increasing Optionality for Additional Platforms and Technologies via Strategic Equity Investments  Potential 1st mover advantage for early data access and partnership opportunitiesBoard observer seats provide opportunities to provide guidance on research and development  29  Equity Portfolio Focus    Direct Equity    LP Venture Capital    Actively Managed Incubators  Description  Direct relationships with innovative companies seen as too early stage or inaccessible for broader partnership~ 75 investments    Deliberately constructed VC portfolio to provide access to innovation across geographies, company stages, TAs and sectors    Partnerships between incubators and BMS support innovation arising from academic centers across multiple geographies  Examples  Pure direct equity: Orna, AktisEquity structured with partnership: Arsenal Bio    Company creation: Avalon BioventuresDedicated focus: Droia Genetic Medicines Fund    Geographic diversity: LAB2030Incubator to Accelerator: Dark Blue Therapeutics  ~$5B total equity investments     

 Integrating AI & Machine Learning into Drug Discovery and Development to Enable Better Decisions and Faster Execution  30        Compound OptimizationReduced cycle times |Computer assisted design  Phenotypic ScreeningNovel targets | CELMoD ® MoA  Biomarker DiscoveryMulti-omics analysis | Digital pathology | Imaging         Protocol Design Competitive positioning | Virtual trial augmentation | Novel endpoints  Hypothesis ValidationLarge internal datasets | Signal detection| Patient selection  Trial ExecutionPatient data collection| Improved Site/Investigator Communication  CTDI  Discovery through Proof-of-concept  Registrational Program Execution  

   BCMA TCE  GSPT1 CELMoD(CC-90009)    Phase 1  POC / initiation of registrational development   Hematology  Fibrosis  Immunology  Oncology   Cardiovascular  Neuroscience  Phase 1 / Phase 2 Pipeline  Anti-SIRPα1(CC-95251)  BCMA CAR T(bb21217)  BET Inhibitor1(CC-90010)  BET Inhibitor (CC-95775)  FXIa Inhibitor  S1PR1 Modulator  TYK2 Inhibitor  Anti-TIGIT  Anti-TIM3  CD3xPSCA2(GEM3PSCA)  STING Agonist  Anti-Fucosyl GM1  Anti-NKG2A3  motolimod  BCMA ADC  milvexian(FXIa Inhibitor)  Opportunity for >20 POC decisions in the next three years  CD19 NEX T3  BCMA NEX T3  Anti-CTLA-4 NF PB  Anti-OX40  FAAH/MGLLDual Inhibitor  AR LDD3  FPR-2 Agonist  CD47xCD203  GPRC5D CAR T3  CD33 NKE3  Anti-CD403  IL2-CD253  LSD1 Inhibitor1  TGFβ Inhibitor  MK2 Inhibitor  HSP47  branebrutinib  Imm. Tolerance (Anokion)2  A/I CELMoD (BCM)(CC-99282)  Anti-CTLA-4 NF  BET Inhibitor(BMS-986158)  Anti-IL-8(BMS-986253)  Anti-CTLA-4 PB  LPA1 Antagonist   FA-Relaxin  afimetoran(TLR7/8 Inhibitor)  danicamtiv  Cardiac Myosin Inh.(MYK-224)  Phase 1b/2  Hematology  Oncology  Immunology  CV  Fibrosis  Neuroscience  Legend  IL-12 Fc(BMS-986415)  Anti-CCR83  TIGIT Bispecific  CK1α CELMoD3  BCMA NKE3  ROR1 CAR-T3  Anti-Tau2,3(PRX005)  BTK Inhibitor3  eIF2B Activator3  AHR Antagonist2(IK-175)  NME  ROMK Inhibitor  1 In development for solid tumors and hematology2 BMS has an exclusive option to license and/or option to acquire3 IND/CTA approved  iberdomide  A/I CELMoD (MM)(CC-92480)  farletuzumab - eribulin ADC  31 

   CC-99282, a novel CELMoD Ikaros/Aiolos degrader optimized for NHL  CC-99282 designed for rapid and maximal substrate degradation profileDemonstrates broad and potent cell autonomous activity (cell death) in DLBCL cell linesSignificant in vivo activity in both ABC and GCB DLBCL xenografts, with regression and tumor free mice on either QD or intermittent schedulesDistribution profile that favors target tissues (lymphoid organs)    Lopez-Girona, A. et al. CC-99282 is a novel cereblon E3 ligase modulator (CELMoD) agent with potent and broad antitumor activity in preclinical models of diffuse large B-cell lymphoma Hematol Oncol. 2021  Protein Homeostasis  32 

 CC-99282-NHL-001a: study design and objective  33  aStudy number NCT03930953; CAR, chimeric antigen receptor; FL, follicular lymphoma; MTD, maximum tolerated dose; PK, pharmacokinetics; RP2D, recommended phase 2 dose; R/R, relapsed or refractory.  Key eligibility criteria (Part A)R/R DLBCL or FL≥ 2 prior regimens including CELMoD agent or CAR T cell therapyOR R/R DLBCL≥ 1 prior regimen and ineligible for transplant  Study endpointsPrimary: safety, tolerability, MTD, RP2DSecondary: PK, preliminary efficacy of CC-99282 monotherapy  Part A: dose escalation  Part B: dose expansion  Objective: To evaluate safety and preliminary efficacy of CC-99282 in R/R DLBCL and FL  Michot J-M, et al. ASH 2021. Abstract #3574  3 distinct intermittent dosing schedules:≥ 3 patients per dosing cohort  RP2D  0.4 mg    0.2 mg  …  0.2 mg    Cohort AR/R DLBCL: CC-99282  Cohort BR/R FL: CC-99282  Cohort CR/R DBLCL: CC-99282 + rituximab  Cohort DR/R FL: CC-99282 + rituximab            Protein Homeostasis 

 CC-99282: Encouraging Early Profile in NHL  Patient baseline characteristic  Overall (n = 35)  Age, median (range), years  66.0 (35–81)  DLBCL, n (%)FL, n (%)  30 (85.7)5 (14.3)  No. of prior anticancer tx, median (range)  3 (1–8)  Failure of last anticancer tx, n (%)  20 (57.1)  Stem cell transplant, n (%)  7 (20.0)  CAR T cell therapy, n (%)  7 (20.0)  Safety  Overall (n = 35)  ≥1 Gr3/4 TEAEs related to CC-99282, n (%)  21 (60.0)  Hematologic TEAEsNeutropeniaFebrile neutropeniaThrombocytopenia  19 (54.3)2 (5.7)3 (8.6)  Nonhematologic TEAEsDiarrheaFatigue  1 (2.9)1 (2.9)  CC-99282 monotherapy showed a predictable and manageable safety profile and demonstrated promising efficacy in heavily pretreated pts with R/R NHL with PK/PD data consistent with robust CC-99282-mediated antitumor activity.   Data cut: 09Apr2021; Michot, JM. et al. Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator(CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/RNHL) – First Results from a Phase 1, Open-Label StudyTo be presented at ASH 2021. Abstract #3574   Best overall responses  * Includes patients who received ≥ 0.4 mg on tolerated dosing schedules CR, complete response; ORR, overall response rate; PR, partial response   Interim PK/PD analyses showed that increase in plasma CC-99282 and degradation of Ikaros/Aiolos in peripheral T cells occurred in a dose-dependent manner where maximum degradation (> 90%) occurred by day 4 of treatment at doses ≥ 0.4 mg    34  Protein Homeostasis 

 CC-95251: A Novel anti-SIRP-alpha Monoclonal Antibody  ADCP, antibody-dependent cellular phagocytosis; FcγR, Fc gamma receptor; NHL, non-Hodgkin lymphoma; SIRPα, signal regulatory protein alpha.  Abstract 2493: Interim results from the first clinical study of CC-95251, an anti-signal regulatory protein alpha (SIRPα) antibody, in combination with rituximab in patients with relapsed and/or refractory non-Hodgkin lymphoma (R/R NHL)Paolo Strati,1 Eliza Hawkes,2 Nilanjan Ghosh,3 Joseph Tuscano,4 Quincy Chu,5 Mary Ann Anderson,6 Amar Patel,7 Michael R. Burgess,7 Kristen Hege,7 Sapna Chhagan,7 Sarandeep Boyanapalli,7 Tracey Day,7 Frank Shen,7 Amitkumar Mehta81The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Austin Health-Austin Hospital, Heidelberg, VIC, Australia; 3Levine Cancer Institute, Charlotte, NC, USA; 4University of California, Davis, Sacramento, CA, USA; 5Cross Cancer Institute, Edmonton, AB, Canada; 6Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; 7Bristol Myers Squibb, Princeton, NJ, USA; 8University of Alabama at Birmingham, Birmingham, AL, USA                              NHL cancer cell           CD47              CC-95251    Antitumor immunity    FcγR  Rituximab    SIRPα                  FcγR  CD20        SIRPα  Reduced negative regulation of phagocytic cells  Increased ADCP  Potential for enhanced adaptive immune response via increased antigen presentation  Macrophage  Phagocytosis          +  Zhang W; et al. Front Immunol 2020;11:18; Sockolosky JT, et al. PNAS 2016;113(19):E2646-54.   35  Biotherapeutic 

 CC-95251: Phase 1 study design and dose schedule  Dose escalation  Dose expansion  aAdministered intravenously. b375 mg/m2; cAdministered at/below the MTD.  Key eligibility criteriaInclusion criteria:CD20+ R/R NHLECOG PS 0–1Disease progression on standard anticancer therapy or no approved conventional therapy availablePrior SCT and CAR T cell therapy permittedExclusion criteria:No prior CD47/SIRPα investigational therapyNo chronic systemic immunosuppressive therapy  Part A objectivesTo determine MTD/RP2DTo assess safety  CC-95251c + rituximabin DLBCL    CC-95251 3 mg/kg + rituximabn = 3  CC-95251 10 mg/kg + rituximabn = 7  CC-95251 20 mg/kg + rituximabn = 7      CC-95251c + rituximabin FL  Rituximaba,b  C6-24: D1 of every other cycle  Abstract 2493: Interim results from the first clinical study of CC-95251, an anti-signal regulatory protein alpha (SIRPα) antibody, in combination with rituximab in patients with relapsed and/or refractory non-Hodgkin lymphoma (R/R NHL)Paolo Strati, et. al. ASH 2021.                          C1  C2  C3  C4  C5  C6   C7  C8                            C1: D1, 8, 15, 22  CC-95251 QWa  C2-5: D1  All 28-day cycles        CAR, chimeric antigen receptor; DLBCL, diffuse large B-call lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; MTD, maximum tolerated dose; NTD, non-tolerated dose; PK, pharmacokinetics; QW, weekly; RP2D, recommended phase 2 dose; SCT, stem cell transplant.  36  Biotherapeutic 

 CC-95251: Encouraging Early Profile in NHL  aRelated to CC-95251; bSafety population; cIncluding a grade 5 septic shock not related to treatment; dEfficacy-evaluable population.AST, aspartate aminotransferase; CR, complete response; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; ORR, overall response rate; PR, partial response; TEAE, treatment-emergent adverse event.   Best overall response  Strati P, et al. Interim results from the first clinical study of CC-95251, an anti-signal regulatory protein alpha (SIRPα) antibody, in combination with rituximab in patients with relapsed and/or refractory non-Hodgkin lymphoma (R/R NHL) ; To be presented at ASH 2021. Abstract 2493.  Baseline patient characteristics  All patients(N = 18)  Age, median (range), years  69 (30–84)  Tumor types, n (%)     DLBCL  14 (78)    FL  2 (11)   MCL  1 (6)   MZL  1 (6)  Prior systemic therapies, median (range)  4 (1–7)  Common TEAEs (> 20 % all grade)  All-cause    Treatment-relateda      Any graden = 17b  Grade ≥ 3n = 17b  Any graden = 17b  Grade ≥ 3n = 17b  Hematologic TEAEs, n (%)           Neutropenia  11 (64.7)  9 (52.9)  9 (52.9)  8 (47.1)   Thrombocytopenia  4 (23.5)  1 (5.9)  3 (17.6)  0  Non-hematologic TEAEs, n (%)           Infection  9 (52.9)  4 (23.5)c  3 (17.6)  1 (5.9)   Hypokalemia  6 (35.3)  0  0  0   Hypomagnesemia  6 (35.3)  0  1 (5.9)  0   Fatigue  5 (29.4)  0  3 (17.6)  0   Headache  5 (29.4)  0  2 (11.8)  0   Infusion-related reaction  5 (29.4)  0  2 (11.8)  0   Nausea  5 (29.4)  0  1 (5.9)  0   AST elevation  4 (23.5)  0  4 (23.5)  0   Hypophosphatemia  4 (23.5)  0  1 (5.9)  0   Increased creatinine  4 (23.5)  0  0  0  37  Biotherapeutic 

 Pleiotropic effects on innate and adaptive immune cells within the TMEStriking antitumor activity in a variety of preclinical models (monotherapy and in combination)  Monovalent IL-12 Fc fusion protein Extended half-life prolonged IFNg PD response, broadening therapeutic indexFirst-in-class opportunity  Narrow therapeutic index with systemically delivered IL-12  BMS-986415: Novel IL-12 Fc Linking Innate and Adaptive Immunity in the Tumor Microenvironment  38  August 2020: Exclusive Global License for Dragonfly's IL-12 Investigational Immunotherapy  Interleukin-12 (IL-12)  Solution: BMS-986415  Therapeutic Challenge  BMS-986415 (IL-12 Fc) – Phase IA  Biotherapeutic 

 CT26: Large Tumors  Preclinical mouse surrogate molecule shows extended PK prolongs PD and provides single agent efficacy  39  Prolonged and Moderate (Peripheral) IFN response  mDF6006 (1 µg single dose)  CT26: Checkpoint-nonresponsive Model   mDF6006 (mouse surrogate of BMS-986415, 1 µg weekly IP or SQ)Tumor volumes are mean values with SEM. *P = 0.0002, **P < 0.0001 with 2-way analysis of variance.aCT26-20.7 subline expressing Tyrp1 tumor-associated antigen; bTwo mice were removed from the isotype group (1 on day 15 and 1 on day 19) due to tumor rupture; cOne mouse was removed on day 19 due to tumor rupture; dOne mouse was removed on day 27 due to tumor rupture.    Preclinical Highlights  Gutierrez, E. et al. Cancer Res July 1 2021 81 (13 Supplement) 1714 Poster presentation at the American Association for Cancer Research Annual Meeting; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA, USA.         Biotherapeutic 

   Study progress: Dose escalation ongoing, no dose limiting toxicities to date  Mono escalation: Enrolling  BMS-986415: Study status and updates  40  Combination escalation with nivolumab: Enrolling  Biotherapeutic 

 Biological Rationale for Targeting the IL-8 Pathway  Primary Hypothesis (Role of IL-8 in Immunosuppressive Tumor Microenvironment):IL-8 blockade will relieve immune suppression induced by PMN-MDSC to enhanced anti-tumor immunity in combination with nivolumab   41  Bakouny, Z., Choueiri, T.K. IL-8 and cancer prognosis on immunotherapy Nat Med 26, 650–651 (2020).  Biotherapeutic 

             Role of IL-8 in Mediating I-O Resistance was Validated using Phase 3 Checkpoint Inhibitor Clinical Trials   42  Schalper KA et al. Nat Med 2020;26:688-692   IL-8 promotes the trafficking of immunosuppressive PMN-MDSCs into TME (CM-017, CM-057)  Reduced OS in CPI Treated Patients with elevated Serum IL-8 (CM-067)    Similar findings in patients with lung, RCC and bladder cancer (NSCLC CM-017/057], RCC CM-025, bladder IMVIGOR-210/211)*    Biotherapeutic 

 BMS-986253: A Novel Anti-IL-8 Monoclonal Antibody shows Preliminary Clinical Activity with Nivo in Melanoma  43  Durable stable disease and partial responses were observed in patients with melanomaPartial responses were observed in 5 of 28 patients with melanoma; all 5 patients with partial response had received prior anti–PD-(L)1, and 4 of the 5 patients had also been previously treated with anti–CTLA-4                                    100  50  -50  0  0  10  20  30  40  Weeks  Melanoma (n = 28)  Change from baseline in tumor burden (%)  50  60  70  80  Response  Progressive disease  Stable disease  Partial response  Treatment ongoing  First occurrence of PR/CR  First occurrence of PD  New lesion  c  c  c  c  b  -100                                                                                                                                                                        aPer RECIST v1.1. Response-evaluable patients, defined as all treated patients with measurable disease at baseline and ≥ 1 postbaseline tumor assessment, clinical progression, or death. 27 of 28 evaluable patients with melanoma had received prior anti–PD-(L)1; 23 of the 28 patients also had prior anti–CTLA-4; bPrior therapy included anti–PD-(L)1; cPrior therapies included anti–PD-(L)1 and anti–CTLA-4.   Davar D et al. Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results. Presented at the SITC 2020 Annual Virtual Meeting; November 9–14, 2020  Biotherapeutic 

 BMS-986253:Pursuing Formal Proof of Concept in a Randomized Ph2 in Post-PD(L)1-Treated Melanoma Patients  44  Arm A: nivo/ipi/anti-IL-8   Randomize All Comers(1:1)  Arm B: nivo/ipi  Stratify by serum IL-8, BRAF and LDH  Patient Population:Unresectable or Metastatic Melanoma, with progression on PD(L)1 inhibitorPD(L)1 as most recent prior therapyCTLA-4 Naïve  Primary Comparison:PFS in sIL-8+ patients Secondary Comparison:PFS in All-Comers Other Endpoints:ORR, OS  Key Study Design ElementsEstablish efficacy in refractory melanoma patients following treatment with anti-PD(L)1 inhibitorsRobust POC study design that confirms contribution of anti-IL-8 therapy to nivo/ipi combination Validation of patient enrichment strategy by conducting primary analysis in sIL-8 positiveStudy design that exhibits probability of regulatory and technical success  NCT03400332: https://clinicaltrials.gov/ct2/show/NCT03400332  Biotherapeutic 

 Innovation Engine provides significant opportunity for pipeline sustainability   Rich and deep pipeline across modalities and therapeutic areasIndustry leading internal discovery platforms across small molecules, complex biologics, protein homeostasis, and cell therapyStrong complementary external network to source emerging innovationPipeline and platform delivering tangible results including within protein homeostasis and biologics   45 

 Samit HirawatChief Medical Officer,Global Drug Development  Late-Stage Pipeline Update 

 Significant progress advancing the pipeline  Cardiovascular - Oncology - Hematology - Immunology  AHAmilvexianmavacamten  ASHBreyanziCELMoDs  Furthering development of expansion opportunities  Advancing science across all key therapeutic areas  Important new data at recent conferences    EADVdeucravacitinib  47 

     Opportunity to extend our leadership in anti-thrombotics  Successful history of developing leading CV medicines  Expand into cardiomyopathies        Opportunity for sustained leadership in Cardiovascular  48    mavacamten  milvexian  Cardiovascular 

       Substantial unmet need persists in thrombotic diseases  Bleeding risk currently limits usage  49  Significant opportunity for an agent with comparable or better efficacy & reduced bleeding risk over Factor Xa inhibitors  Patients with high bleed risk also at higher thromboembolic risk  Concerns today with combining OACs & dual-antiplatelet therapy  Opportunity to enhance benefit/risk  Room to advance carebeyond substantial advances of FXa  Many patients remain untreated or undertreated (with respect to anticoagulation) due to bleeding risk   Cardiovascular 

   MOA supports opportunity to improve benefit/risk profile with an oral FXIa inhibitor  50  Extrinsic Pathway  Intrinsic Pathway  Tissue Factor  FVIIa  FVII  Vesselinjury  Common Pathway  FXII  FXIIa  FIX  FIXa  FX  FXa  FII  FIIa/Thrombin  FXI  FXIa    Thrombin Feedback               apixaban    milvexian    Cardiovascular 

 Milvexian Phase 2 trials will inform optimal dose/regimen for Phase 3 program  Positive trialFull data presented at AHA 2021 & in NEJM*      Secondary Stroke Prevention (SSP) Study Milvexian + clopidogrel + aspirin vs placebo + clopidogrel + aspirin in patients with acute ischemic stroke or transient ischemic attack(N=2350)    Total Knee Replacement (TKR) StudyMilvexian vs enoxaparin in patientsundergoing elective total knee replacement surgery(N=1242)  Readout expected 1H 2022  51  Cardiovascular  *published November 15, 2021 at https://www.nejm.org/doi/full/10.1056/NEJMoa2113194?query=featured_home 

                   Milvexian Phase 2 TKR trial design  Milvexian vs enoxaparin*Open-label multicenter, dose-ranging study 25 mg to 400 mg total daily dose10 to 14 day exposureStudy objectives:To demonstrate effectiveness in preventing total VTE events during treatment periodTo assess the dose response of milvexian for the occurrence of bleeding events  52      1242subjects  R    milvexian 25 mg BID(153)    milvexian 50 mg BID(150)    milvexian 100 mg BID(152)    milvexian 200 mg BID (153)    Open-Label enoxaparin SC 40 mg QD(301)    milvexian 50 mg QD†(150)    milvexian 200 mg QD(149)    milvexian 25 mg QD †(34)  *enoxaparin @ 40-mg daily dose† Milvexian 25 mg QD stopped by Operations committee, replaced by milvexian 50 mg QD  Cardiovascular 

 Profile of milvexian is differentiated from existing anti-thrombotics  53  N*: based on efficacy (ITT) data set      enoxaparin, mg    milvexian, mg              N*    40 mg QD (n=252)    25 mg QD (n=28)  50 mg QD(n = 127)  25 mg BID(n = 129)  50 mg BID(N = 124)  200 mg QD (n=123)  100 mg BID (n=134)  200 mg BID (n=131)  All VTE + all death    21.4    25.0  23.6  20.9  11.3  6.5  9.0  7.6  All Bleeding, %    4.1    0  5.3  1.4  4.7  6.1  4.7  3.4  Major or CRNM Bleeds    1.7    0  1.3  0  1.4  0.7  0.7  0.7  - Major    0.3    0  0  0  0  0  0  0  - CRNM    1.4    0  1.3  0  1.4  0.7  0.7  0.7  - Minor    2.7    0  4.0  1.4  3.4  5.4  4.7  2.7    Robust efficacy with clear dose-response  Low risk of bleeding  No major bleeds observed in milvexian arms  No dose response in bleeding observed in doses ≥50 mg -> distinct from existing anticoagulants  Note: CRNM bleeds = clinically relevant non-major bleeds  Cardiovascular 

 Scientific community recognizes important data for Milvexian, potential next generation anti-thrombotic  54  Cardiovascular 

 Milvexian Phase 2 SSP trial design  55  Topline data expected 1H 2022  Study objectives:Provide data on top of dual anti-platelet therapyAssess longer exposure — up to 90 day treatmentFurther insight into efficacy and bleeding profile    \                2350subjects  R    Arm A – placebo + 100 mg aspirin + 75 mg clopidogrel    Arm B – milvexian 200 mg BID + 100 mg aspirin + 75 mg clopidogrel    Arm C – milvexian 100 mg BID + 100 mg aspirin + 75 mg clopidogrel    Arm D – milvexian 50 mg BID + 100 mg aspirin + 75 mg clopidogrel    Arm F – milvexian 25 mg QD + 100 mg aspirin + 75 mg clopidogrel    Arm E milvexian 25 mg BID + 100 mg aspirin + 75 mg clopidogrel  Cardiovascular 

       Multiple potential opportunities for novel antithrombotic  Anti-platelets1SSPACSCAD/PAD  Factor Xa1VTEAFIB  Potential universe of indications    Milvexian  Optionality for Ph3 program pending SSP Ph2 results    SSP = secondary stroke prevention; ACS = acute coronary syndrome; CAD = coronary artery disease; PAD = peripheral artery disease; VTE = venous thromboembolism (prevention and/or treatment-related indications); AFIB = atrial fibrillation  1Represents indications with majority of usage  56  Cardiovascular 

         Opportunity to improve outcomes for patients on existing treatments  Milvexian: significant opportunity for next generation anti-thrombotic  Ph3 program expected to begin as early as 2H 2022  57  Similar or better efficacyBetter bleeding profile  Clear benefit over enoxaparin No major bleeds observed; no dose response in bleeding ≥50mg BID  Expected to further define the profile  TKR Phase 2 data demonstrate differentiated anti-thrombotic profile  SSP data expected 1H 2022  Registrational program planningin progress  Cardiovascular 

   Hypertrophic cardiomyopathy (HCM) disease profile    Significant unmet need for symptomatic HCM  Thickening of the heart muscle due to:hypercontractility — impaired relaxation — hypertrophyAffects 1 in 500 people; most common genetic heart disease Symptoms include: palpitation, dizziness, breathlessness, tiredness, chest pain, sudden cardiac arrest  58  Hypertrophic Heart  LVOT1 obstructionDecreased left ventricular volumeThickened heart muscle and septum  Normal Heart  1. LVOT = Left ventricular outflow tractSource: Olivotto. Lancet. 2020; Maron. NEJM. 2018; Marian. Circ Res. 2017; Maron. J Am Coll Cardiol. 2016; Veselka. Lancet. 2016; Maron. J Am Coll Cardiol. 2015; Ahmad. Annu Rev Genomic Hum Genet. 2005; Maron. JAMA. 1999; Maron. Circulation. 1995.   Currently no approved medicines that address underlying disease  Diagnosed by echo-cardiogram  Typical age of diagnosis in the ~40s-50s  Subset of patients have severe symptoms  Current therapeutic options limited to symptom-treating generic drugs (e.g., beta-blockers)  Cardiovascular 

       Mavacamten: a potential first-in-class medicine that addresses underlying disease in oHCM   Marked improvements in cardiac function & symptoms: 65% pts improved by ≥ 1 NYHA class (vs 31% with placebo)Clinically meaningful reduction in LVOT gradients; sustained reduction in key cardiac biomarkers Positive impact on health statusWell tolerated safety profile  59  PDUFA: Jan 28, 2022  ESC 2020: Positive Ph3 results from EXPLORER-HCM  ACC 2021: Long-term data from the EXPLORER cohort ofMAVA-LTE show durability of improvement & confirm safety profile  NYHA = New York Heart Association    Cardiovascular  Olivotto, et al, Lancet 2020Rader, et al, J Am Coll Cardiol, 2021 May, Supplement 

 Expanding the oHCM label with VALOR-HCM  60  Primary EndpointComposite ofdecision to proceed with SRT prior to or at wk 16+ SRT guideline eligible at wk 16, but declined   VALOR-HCM Study Design  Patients with symptomatic oHCM, eligible for SRT*N=100 (US only)  1:1 Randomization  mavacamten2.5,5,10,15 mg QD  placebo (thru wk 16)  Treatment phase 32 wks               Long-term extension to wk 136  Potentially registrational trialDemonstrate mavacamten’s potential in high-risk patients and prevent the need/eligibility for highly invasive SRTData expected in 2022  * Septal reduction therapy  mavacamten 2.5,5,10,15 mg QD  Cardiovascular  Desai, et al, Am Heart J, Sep 2021 

 AHA 2021 (abstract #9685)Long term data demonstrate:Sustained NT-proBNP reductionImprovement in cardiac fill & function, as measured by E/e’ & LAVI No new safety signals  Median (IQR) NT-proBNP over time in the total population (N = 43)    Data from MAVERICK, & MAVERICK cohort of MAVA-LTE support Ph3 initiation in nHCM in 2022  Improvement in myocardial wall stress, as measured by NT-proBNP cardiac biomarkerWell tolerated safety profile  61  ACC 2020: Positive Ph2 results from MAVERICK-HCM    Note: E/e’ is an echocardiographic measure of filling pressures in the heart; LAVI = left ventricular volume index  Cardiovascular  Ho, et al, J Am Coll Cardiol, Jun 2020 

 Mavacamten indications and pipeline opportunities  62  P1  P2  P3  Mavacamten has potential to make a significant impact in the CV space, starting with oHCM    EXPLORER-HCM  oHCM NYHA ClassII & III completed  oHCM potential SRT alternative    VALOR-HCM    MAVERICK-HCM and MAVA-LTE  nHCM    EMBARK-HFpEF  Precision diastolic disease (HFpEF)  oHCM PDUFA: January 28, 2022  Topline data expected in 2022  Ph2 MAVERICK & MAVA-LTE data informing plans to initiate Ph 3 in 2022  Ph2 POC initiated  Cardiovascular 

 Advance broad early pipeline  Leverage leading expertise in hematology  Expand key new medicines        Opportunity to advance leadership in Hematology  63    Hematology 

 CC-92480CC-92480+bort+dex in 4L+ MM patients (presentation #2731)Differentiated potency supported by encouraging clinical combination data  Upcoming ASH data support important progress advancing hematology pipeline  1st cell therapy to demonstrate benefit over SOC 2L LBCL data (TRANSFORM) (presentation #91)  64  Encouraging new data on early pipeline assetsGPRC5D CAR T (MSKCC abstract #153204)CC-99282 (presentation #3574) & SIRPα (presentation #2493)  IberdomideIber+dex in 4L+ MM patients (presentation #162)Profile supports advancing therapy in earlier lines  Hematology 

 Breyanzi TRANSFORM data: demonstrates further potential of Cell Therapy treatments   65  Supports Breyanzi as potential new SOC for 2L treatment in R/R LBCL  mEFS = 10.1 (95% CI, 6.1–NR); HR=0.349;P < 0.0001   Primary endpoint: mEFS  ORR = 86% (95% CI, 77%–92.3%)P < 0.0001   Secondary endpoint: ORR    First therapy to demonstrate benefit vs. SOCStatistically significant & clinically meaningful improvement in primary & and key secondary endpointsNo new safety concerns:  CRS all grades: 49% CRS Gr3:< 1%NE all grades: 12% NE Gr3: 4%   Data from ASH abstract  Hematology 

 Continuing to expand Breyanzi  Best-in-class CD19*Strong efficacy demonstrated in 2L and 3L+ LBCLDifferentiated side effect profile, incl. low rates of CRS & NE  66  Registrational program & data availability  TRANSFORM 2L TE (Breyanzi vs SOC)  TRANSCEND-CLL-004   Phase I  Phase II  Pivotal  PILOT 2L TNE (single arm)  TRANSCEND FL 3L+  ASH 2021  LBCL   iNHL (FL & MZL)  3L+ CLL  2022  2023  2021  2L+ CLL  Study planned  Hematology  *lower rates of Gr3/4 CRS and NE 

 CELMoDs could replace the current foundation of care  67  1L  2L  3L  4L  Revlimid today    Pomalyst today  Replace Revlimid as foundation of frontline multiple myeloma treatment  Iberdomide vision  Replace Pomalyst as foundation of treatment in relapsed refractory multiple myeloma (RRMM)  CC-92480 vision  Success Factors  Demonstrate superiority to IMiD agents (Revlimid, Pomalyst)Combine CELMoDs broadly with existing SoCEstablish proprietary novel combinations to displace SoCDevelop multiple assets to enable sequential treatment  Data to be presented at ASH support strategy      Hematology 

 Iberdomide: CC-220-MM-001: Phase 1b/2a study design  68  RRMM, prior len or pomPrior proteasome inhibitorDocumented PD during or within 60 days of last anti-myeloma therapy    Cohort D:iber (1.6mg qd, RP2D) + dex  Cohort E: iber + dara + dex(iber: 1.0mg qd-1.6mg qd)    Study endpoints:Primary: to determine MTD/RP2D and efficacy Secondary: to assess safety   Phase 1: Dose Escalation  Phase 2: Dose Expansion  Cohort C: iber (RP2D)   Data at ASH 2021  Cohort B: iber + dex(iber: 0.3mg to 1.6mg qd)  Cohort A: iber (iber: 0.3mg qd-1.0mg qd)  Cohort F: iber + bort + dex(iber: 1.0mg qd-1.6mg qd)  Cohort G: iber + cfz + dex(iber: 1.1mg qd)  Refractory to 3+ prior regimens incl: Len, Pom, PI, glucocorticoid & CD38; excl. prior BCMA therapy  Refractory to 3L+, post BCMA  Cohort I:iber (1.6mg qd, RP2D) + dex (post-BCMA)  Hematology 

   Note: all data shown on slide per ASH 2021 abstract; data to be presented    Cohort D  Grade 3-4 TEAEs:     neutropenia  44.9%  anemia   28%  thrombocytopenia   21.5%  leukopenia  20.6%  GI disorders  5.6%  fatigue  2.8%  rash  1.9%  dose interruptions due to TEAEs  52.3%  dose reductions due to TEAEs  18.7%  discontinuances due to TEAEs  4.7%*   Iberdomide + dex: Profile to date supports advancing combination therapies into earlier lines of treatment   69  Encouraging response rates in a 4L+ population, including those pts refractory to IMiDs25% in patients who are post-BCMA treatmentFavorable tolerability profile support combination therapy; e.g., low rates of GI, fatigue, rash, discontinuations  ORR 26.2%  ORR 25%  Manageable safety profile  Cohort D  Cohort I  *No pts discontinued iber due to neutropenia      Hematology 

   Iberdomide triplet combinations: Promising responses & manageable safety profile in heavily pretreated patients  70  ORRa 45.9%  ORRa 56%  ORRa 50.0%  aPR or better; bIncludes neutropenic sepsis. Lonial S, et al. Oral presentation at EHA 2021; abstract S187  Cohort E  Cohort F  Cohort G  Favorable safety profile    Grade 3 TEAEs   Cohort E  Cohort F  Cohort G  neutropenia  66.7%  28.0%  33.3%  anemia   20.5%  12.0%  0%  thrombocytopenia   12.8%  24.0%  11.1%  febrile neutropeniab  5.1%  0%  0%  fatigue  2.6%  0%  11.1%  diarrhea  2.6%  4.0%  0%  rash  0%  4.0%  0%  infections  15.4%  20%  33.3%  Data support moving into earlier lines  Increased response rates in combination with multiple standard MM therapiesFavorable tolerability maintained, e.g. fatigue, diarrhea, rash  Hematology 

 EXCALIBER NDMM (TNE):Iber+bort+dex / iber+dara+dex, vs. RVd  Iberdomide: Plans to develop as a new backbone in early line MM   71  2L+  Post transplant maintenance:Iber vs. Revlimid  EXCALIBER RRMM:Iber+dara+dex vs. dara+bort+dex  NDMM  NDMM  2023  2023  Expected initiation timing  1H 2022  Hematology 

 CC-92480-MM-002: study design and objective  72  Key eligibility criteria (Cohort A)RRMM; 2–4 prior regimens including LENDisease progression during or after their last antimyeloma therapy  Study endpointsPrimary: to determine MTD/RP2D and to assess safety and preliminary efficacySecondary: to evaluate additional efficacy measures  Phase 1: dose escalation  Cohort ACC-92480a + bort + dex  Cohort BCC-92480 + dara + dex  Cohort CCC-92480 + cfz + dex  Cohort HCC-92480 + elo + dex  Cohort ICC-92480 + isa + dex  Phase 2: dose expansionb (1-3 prior lines)  ClinicalTrials.gov: NCT03989414EudraCT: 2018-004767-31    Cohort DCC-92480c + bort + dex  Cohort ECC-92480c + dara + dex  Cohort FCC-92480c + cfz + dex  Cohort JCC-92480c + elo + dex  Cohort KCC-92480c + isa + dex  Cohort G/NDMMCC-92480c + bort + dex  a0.3, 0.6, or 1.0 mg given orally on days 1–14 of each 21-day cycle. bIf the threshold for minimum ≥ VGPR rate for Cohort D is met, an additional cohort may be opened to evaluate CC-92480 + BORT + DEX in TE NDMM patients; cAt RP2D. BORT, bortezomib; CFZ, carfilzomib; DARA, daratumumab; DEX, dexamethasone; ELO, elotuzumab; ISA, isatuximab; LEN, lenalidomide; MTD, maximum tolerated dose; NDMM, newly diagnosed multiple myeloma; RP2D, recommended phase 2 dose; TE, transplant eligible.  Hematology 

 Differentiated potency for CC-92480 supported by encouraging clinical combination data  73  CC-92480 & dex: Scan from expansion phase  Patient with EMP, extramedullary plasmacytoma  The median duration of response was 10.4 (5.5–not reached) months Median time to response was 0.95 (0.7–3.3) months  aPR or better; C, cycle; CBR, clinical benefit rate; CR, complete response; DCR, disease control rate; Exp, exposed; MR, minimal response; NE, not evaluable; ORR, overall response rate; PD, progressive disease; PR, partial response; Ref, refractory; reg, regimen; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response.  Safety  CC-92480 + bort + dex   neutropenia Gr 3-4  36.9%  thrombocytopenia Gr 3-4   21.1%  anemia Gr 3-4  10.5%  hyperglycemia Gr 3-4insomnia Gr 3-4  10.5%10.5%  CC-92480 triplet combination: Strong response rates & favorable safety mainly in 4L+  ORRa 73.7%  All data shown per ASH 2021 abstract; data to be presented  CT at screening  CT post treatment  Hematology 

 CC-92480: Potential opportunity to replace Pomalyst for 2L+ MM patients  74  4L+  CC-92480 + dex  Status:  Ph2 ongoing to inform Ph3 program  CC-92480+Vd vs PVd; CC-92480+Kd vs Kd  2L+  Expected to initiate registrational trials in 2023  CC-92480 + dex + bort / cfz / dara / isa / elo  Ph2 ongoing to inform Ph3 program  Hematology  POC  Registrational  2L+ 

   Advancing our BCMA portfolio  75  1 In partnership with Dragonfly2 In partnership with Sutro3 In partnership with 2seventy bio      Immune Cell Engagers  Antibody Drug Conjugate  T-Cell Engager CC-93269Encouraging early IV dataProgram now focused on subcutaneous formulationto maintain efficacy & reduce CRSNK-Cell Engager BMS-9863921New asset in Ph1Potential potent tumorkilling ability & less CRS  ADC CC-997122Designed to avoid toxicity associated with other BCMA ADCsCurrently in dose ranging studies    CAR T  In market with 1st in class BCMA CAR T3 with strong demandNew wave of innovation with NEX T enables manufacturing efficiencies  Hematology 

     Important progress advancing our Multiple Myeloma strategy  76  STRATEGIC OBJECTIVES  Potential to improve upon IMiD agents and create new backbone   Establish BCMA as theoptimal MM target  Redefine SoC acrosslines of therapy  BCMA targeting agents  CELMoD agents  Strategic objectives      Combinations      Continued innovation from early pipeline, e.g. GPRC5D CAR T  Hematology 

 Robust Hematology Pipeline  77  Phase 1  Phase 2  Marketed  iberdomide  BCMA TCE  CD33 NKE  BCMA NKE  BCMA CAR T(bb21217)  ROR1 CAR T  A/I CELMoD(CC-92480)  CK1α CELMoD  BCMA NEX T  CD19 NEX T  BET Inhibitor(BMS-986158)  A/I CELMoD(CC-99282)  GSPT1 CELMoD(CC-90009)    Anti-SIRPα1  Pivotal  Expansion opportunities:  Reblozyl 1L MDS  RebloyzlMF  Breyanzi 3L+ CLL  Breyanzi 3L+ iNHL  Abecma 3-5L MM  Breyanzi2L TE/TNE LBCL  GPRC5D CAR T  1 In development for solid tumors and hematology 2 BMS has an exclusive option to license and/or option to acquire  BCMA ADC  CD47xCD20  BET Inhibitor1(CC-95775) 

 Diversify beyond I-O with differentiated platforms & novel MOAs  Continue to expand Opdivo / Yervoy  Extend I-O leadership through the next-generation of assets       Leverage expertise to broaden & diversify in Oncology  78    Oncology  rela+nivo FDC  bempeg  MORAb-202 ADC 

   Continuing to grow Opdivo / Dual I-O  1 as part of collaboration with NEKTAR 2 potential applicability in both metastatic & early stage disease    Metastatic Setting        Tumor/Trial  Status  Tumor/Trial  Status  1L MelanomaCA045-001Opdivo + bempeg1 vs Opdivo  1H 2022 Readout  Prostate (mCRPC)CM-7DXOpdivo + Chemo vs Placebo + chemo  2023+Readout   1L HCC CM-9DW Opdivo + Yervoy vs sorafenib / lenv.  2023+ Readout  Subcutaneous nivolumab2CM-67T  2024 Readout  MSI-H CRCCM-8HWOpdivo + Yervoy  2025Readout      Early-Stage Setting        Tumor/Trial  Status  Tumor/Trial  Status  HCC (Adj)CM-9DXOpdivo vs Placebo  2023Readout  NSCLC (Adj)ANVILOpdivo vs Observation  2024Readout  NSCLC (Neo-Adj)CM-816Opdivo + chemo vs chemo  2020 pCR 2023+ EFS  NSCLC Stage 3 (Unresectable)CM-73LOpdivo mono, O+Y vs Imfinzi  2023+Readout  Renal (Adj)CM-914Opdivo + Yervoy vs Placebo  2022 / 2023Readout (Part A)  NSCLC (Peri-Adj)CM-77TNeo-adj Opdivo + chemo followed by Adj Opdivo vs chemo  2024Readout  MIBC (Peri-Adj)CA017-078Opdivo + Chemo,Opdivo + IDO + chemo, vs chemo  2024Readout  Melanoma (Adj)CA224-098Relatimab + Opdivo vs Opdivo  2025 Readout  22  OPDIVOapprovals  10  YERVOYapprovals  11  tumors  79  Oncology 

 a Per BIPR; pCR: 0% residual viable tumor cells in both primary tumor (lung) and sampled lymph nodes; b ITT principle: patients who did not undergo surgery counted as non-responders for primary analysis; c Calculated by stratified Cochran–Mantel–Haenszel method; d pCR rates 95% CI: NIVO + chemo, 18.0–31.0; chemo, 0.6–5.6  Expanding Opdivo use in early-stage lung cancer  Across neo-adjuvant, adjuvant and peri-adjuvant settingsUtilizing both mono & combination approaches  CM-816: Neo-adjuvant nivo + chemo  80  ANVIL Adjuvant Opdivo  CM -77T Peri-adjuvant  CM -73LStage 3 unresectable  CM -816 Neo-adjuvant Opdivo + chemo  2.2%d   OR = 13.94 (99% CI, 3.49–55.75)cP < 0.0001   Differencec21.6%  24.0%d   n/N 43/179 4/179  ITT (ypT0N0)b  2) Clinically meaningful EFS data in-house; to discuss with health authorities    1) Primary endpoint of pCRa met vs chemo  Multiple opportunities in early-stage lung  Oncology 

 Next novel I-O combination: relatlimab + nivolumab   81  LAG-3 and PD-1 are distinct immune checkpoints, often co-expressed on tumor-infiltrating lymphocytes, and contribute to tumor-mediated T-cell exhaustion1,2In preclinical models, LAG-3 and PD-1 blockade demonstrated synergistic antitumor activity1​  APC, antigen-presenting cell; MHC, major histocompatibility complex; TCR, T-cell receptor.1 Woo S-R, et al. Cancer Res 2012;72:917–927; 2 Anderson AC, et al. Immunity 2016;44:989–1004   Clinical data support potential opportunities in melanoma (PDUFA: Mar 19, 2022) & beyond    RELA + NIVO (n = 355)  NIVO(n = 359)  Median PFS, months  10.12  4.63   (95% CI)  (6.37–15.74)  (3.38–5.62)  HR (95% CI)  0.75 (0.62–0.92)    P value  0.0055    RELATIVITY-047 in 1L mel  Oncology 

 Rela + Nivo FDC: broad expansion program  82  Melanoma  NSCLC  1L – Relativity -047  Adjuvant (Stage 3/4): CA 224-098 rela+nivo vs nivo  1L: CA224 -095 rela+nivo+chemo vs pembro+chemo  HCC  1L: CA224 -106 rela+nivo+bev vs nivo+bev  2L IO naïve: CA224 -073rela+nivo vs nivo   1L: CA224 -104 rela+nivo+chemo vs nivo+chemo    In regulatory review (PDUFA: Mar 19, 2022)  Registrational study    POC to trigger registrational study         Planned; not yet enrolling  Ability to leverage ongoing data generation to inform future expansion opportunities  CRC  2L+: CA224 -123rela+nivo vsregorafenib  Oncology 

 Pegylated IL-2 partnered with NEKTAR Therapeutics        Bempeg: additional next generation I-O opportunity  83  Melanoma  Renal  Adjuvant Mel: PIVOT-12nivo+bempeg vs. nivo2Readout: 2025  Bladder  Peri-Surgical MIBC: CA045-009 nivo+bempeg vs. nivo vs. SOC1Readout: 2023  1L cis-ineligible: PIVOT-10nivo+bempeg2Readout: 1H 2022    1BMS operationalized; 2 NKTR operationalized  1L Mel: CA045-001nivo+bempeg vs. nivo1Readout: 1H 2022  1L RCC: PIVOT-09nivo+bempeg vs. TKI2Readout: 2H 2022  Note: CDP also includes earlier solid tumor studies (e.g., PIVOT-02), regional studies (e.g., Japan ‘010, China ‘016), and pediatric studies (e.g., ‘020) not depicted here.     Ongoing registrational opportunity    Oncology 

 MORAb-202 is a novel folate receptor alpha ADC  84  Differentiated payload (eribulin) Demonstrated single agent clinical activity across multiple tumor types  In partnership with EisaiTumors of interest include ovarian, NSQ NSCLC, breast, endometrialHigh addressable population based on range of FR expression  Development plan  Interim analysis of Phase I study ongoing in Japan      ORR*3: 46%DCR*4: 82%(RECIST v1.1*5)  Expansion cohort is ongoing in FRα positive platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC)  Percentage of change from baseline (%)  Breast   Endometrial   NSCLC  Ovarian   Fallopian tube  Next stepsEvaluating dose range to optimize therapeutic index  Potential to further diversify solid tumor portfolio & extend leading position in Oncology  Oncology 

   Phase 1  Phase 2  Phase 3  Marketed  Robust Oncology Pipeline  Anti-Fucosyl GM1  Anti-OX40  STING Agonist  Anti-NKG2A  motolimod  Anti-TIM3  Anti-CTLA-4 NF  Anti-CCR8  Anti-CTLA-4 Probody  AR LDD  CD3xPSCA(GEMoaB)2  Anti-IL-8  Anti-TIGIT  relatlimab1  bempegal-desleukin  linrodostat  TGFβ Inhibitor  LSD1 Inhibitor1  BET Inhibitor1(CC-90010)  AHR Antagonist(Ikena)2  IL-12 Fc  Anti-CTLA-4 NF-Probody  TIGIT Bispecific  farletuzumab - eribulin ADC   subcutaneous nivolumab    >20 assets in Phase 1 / 2  1 In development for solid tumors and hematology2 BMS has an exclusive option to license and/or option to acquire  85 

 Multiple promising early assets across immune-mediated diseases   Foundation in Immunology today  Expansion opportunities underway        Building an exciting pipeline in Immunology    Rheumatology / Gastroenterology / Dermatology    (CD)  86  (MS,UC)  Immunology  deucravacitinib  cendakimab 

 DeucravacitinibA first-in-class selective TYK2 inhibitor in moderate-to-severe psoriasis, with proven differentiation   Deucravacitinib has potential to become new oral standard of care in psoriasis  87  Clinically meaningful efficacySuperior to apremilast, comparable to1st generation biologicsDurable responses through one yearFavorable safety and tolerability Consistent with its mechanism of action Opportunity for broad applicability across a range of immune-mediated diseasesFiled in U.S. & EU (PDUFA Sept 2022)   Immunology 

 Missing data were imputed using nonresponder imputation.sPGA response defined as a score of 0 or 1, with ≥2-point improvement from baseline.PASI, Psoriasis Area and Severity Index; PASI 75, ≥75% reduction from baseline in PASI; PASI 90, ≥90% reduction from baseline in PASI; PASI 100, 100% reduction from baseline in PASI; sPGA 0/1, static Physician’s Global Assessment score of 0 or 1.  Long-term data further support differentiated efficacy profile  1  2  65.1%  44.0%  19.3%  58.4%  35.5%  14.2%  PASI 75  PASI 90  PASI 100  53.6%  17.5%  1  2  sPGA 0/1  sPGA 0  52.7%  23.5%  Primary endpoint  Primary endpoint  PASI 75, PASI 90, PASI 100 responses for deucravacitinib (n=332)  Meaningful responses sustained through wk 52 across primary & secondary endpoints  sPGA 0/1 and sPGA 0 responses for deucravacitinib (n=332)  88  Not for Product Promotional Use  Immunology 

 Labels for approved JAK 1,2,3 inhibitors reflect known JAK lab signature    tofacitinib  upadacitinib  baricitinib  MOA(in vitro JAK 1-3 selectivity)  JAK 1, 2, 3  JAK 1, 2    Anemia (Hemoglobin)  Do not initiate in pts with< 9 g/dLInterrupt in pts with < 8 g/dL or decrease of >2 g/dLMonitoring for potential changes  Do not initiate in pts with < 9 g/dLInterrupt in pts with < 8 g/dL Decreases to < 8 g/dL were reported in clinical studiesMonitoring for potential changes    ALT/AST (Liver Enzyme)  Increased incidence of liver enzyme elevationRoutine monitoring of liver tests recommended      Lipids  Increases in total cholesterol, LDL, & HDLRoutine monitoring recommended      89  Note: Tofacitinib: maximum effects within 6 weeks; dose dependent increases in total cholesterol, LDL, HDL  Immunology 

 Results through one year confirm no clinically meaningfulchanges from baseline and no JAK-like signature across lab results  Graphs display as observed data for patients randomized to deucravacitinib at baseline in PSO-1 who continued treatment until Week 52.LLN, lower limit of normal; QD, once daily; ULN, upper limit of normal.   90  8  16  0  24  52  Total Cholesterol  ULN  LLN  Mean ± SD, mg/dL  1  2  4  8  12  16  0  20  24  28  32  36  40  44  48  52  LLN  ULN  ALT  Mean ± SD, U/L  Mean ± SD, g/dL  Hemoglobin  1  2  4  8  12  16  0  20  24  28  32  36  40  44  48  52  LLN  ULN  Platelets  ULN  Mean ± SD, 109/L  1  2  4  8  12  16  0  20  24  28  32  36  40  44  48  52    Weeks  Weeks  Weeks  Weeks  LLN  Immunology 

   Deucravacitinib Ph 3 study ongoing in Psoriatic Arthritis   91  Data from Phase 2  Primary endpoints:ACR20Secondary endpoints included:DAS28-CRPHAD-DI (disability index questionnaire)PASI-75  Phase 3 Program (moderately to severely-active PsA)  Deucravacitinib in Psoriatic Arthritis (PsA)  Deucravacitinib demonstrated significantly greater ACR20 responses at wk 16: 52.9% (at 6 mg) vs 31.8% (placebo)  IM011-054  IM011-055  Nominal P values for pairwise comparison vs placebo. P values in time course are for odds ratios obtained using a stratified Cochran-Mantel-Haenszel test with stratification factors (body weight and prior TNFi use) per randomization. Missing data were reported using NRI. *P = 0.0108 (12 mg). †P = 0.0021 (6 mg); P = 0.0021 (12 mg). ‡P = 0.0134 (6 mg); P = 0.0004 (12 mg). ACR20, American College of Rheumatology, 20% improvement in response; ITT, intent to treat; NRI, nonresponder imputation; QD, once daily; TNFi, tumor necrosis factor inhibitor.Included with permission from Mease PJ et al. Poster presentation at ACR Convergence 2020; November 5-9, 2020; Poster L03. 1  ACR20 at Week 16 (ITT, NRI)    p = 0.0004  p = 0.0134    Placebo      Deucravacitinib6 mg QD  Deucravacitinib 12 mg QD    Readout: 2024  Immunology 

 Opportunity to evaluate the potential for deucravacitnib in two important inflammatory bowel diseases  Ulcerative ColitisInitial Ph2 study in moderate-to-severe UC (LATTICE-UC) did not meet primary & key secondary endpointsSecond Ph2 trial (IM-024-127, below) to assess potential at higher dose, with opportunity to expand – data expected 2022/2023  92  Crohn’s DiseaseOngoing Ph2 in Crohn’s Disease (LATTICE-CD)Data expected 2022/2023  Rollover LTE study        DeucravacitinibDose 1    DeucravacitinibDose 2    Placebo       R      Open-Label Deucravacitinib  Week 0Endoscopy/Biopsy  Week 12Primary endpointEndoscopy/Biopsy  Week 52Endoscopy/Biopsy  Screening  Double-Blind Treatment Period  Open-Label Treatment Period  4 weeks  12 weeks  40 weeks  Follow-Up  4 weeks      No: Discontinue IP & enter post-treatment follow-up        DeucravacitinibDose 1    DeucravacitinibDose 2    Placebo      R      Week 0Endoscopy/Biopsy  Week 12Primary endpointEndoscopy/Biopsy  Week 52Endoscopy/Biopsy  Screening  Induction Period  Maintenance Period  28 days  12 weeks  40 weeks    Clinical response at week 12  No: Switch to OL arm  OL Deucra-vacitinib  Clinical response at Wk 26  YES: Treat-throughDeucravacitinib  YES: Treat-throughDeucravacitinib  YES: Treat-throughPlacebo  OL Deucra-vacitinib  YES: Continue on OL arm  Loss of response  Immunology 

   Additional expansion opportunities for deucravacitinib  93  Psoriatic Arthritis  Registrational  Ongoing Ph 2 POC  Psoriasis  Systemic Lupus Erythematosus  Crohn’s Disease  Ulcerative Colitis  Filed in U.S. & EU  IM-011-127 Phase 2expected 2022/2023  Phase 3 enrolling; Readout: 2024  Readout: Early 2022  Readout: 2022/2023  Discoid Lupus Erythematosus   Readout: 2H 2023  Psoriasis topical (Mild-to-moderate)  Phase 2 to begin mid-2022  Dermatology  Rheumatology  Gastroenterology  New Ph 2 POC  Ability to leverage ongoing data generation to inform future expansion opportunities  Immunology 

     Established IBD presence with Zeposia UC,with potential expansion to Crohn’s Disease  94  Primary endpoints:Induction studies: Week 12 clinical remissionMaintenance study: Co primary @ Week 52 clinical remission and endoscopic response  Crohn’s Ph 3 Study Design (YELLOWSTONE)  Zeposia in IBD  Zeposia  Placebo  Zeposia  Placebo  Zeposia responders or remitters are re-randomized 1:1 to Zeposia or Placebo  Zeposia  Placebo  52 wk maintenance study    Study 3201    Study 3202  N = 400  N = 200  N = 400  N = 200  12 wkinduction study  Adults with moderately to severely active CD  Ulcerative Colitis — Currently approved in the U.S.; positive CHMP opinion  Zeposia currently provides UC patients with efficacy comparable to biologics, and a favorable safety profile in an oral medicine  Provides opportunity to benefit additional patients living with IBDReadout: 2024  Crohn’s Disease — Phase 3 trial enrolling    Immunology 

   EoE Overview:High unmet need, currently no approved therapiesLife altering disease for ~700k pts (combined U.S./EU5)    EoE: POC established with Ph2 data   Continuing to build with cendakimab  High affinity IL-13 neutralizing antibody  95  IL-13Ra1  IL-13Ra2  Fibrosis & Remodeling      IL13  IL13  Inflammation  X  X  Cendakimab  Binds to IL-13 ligandInhibits IL-13Ra1 & IL-13Ra2 subunitsPotential to address both inflammation & fibrosis/remodeling  Co-primary (week 24):Change in dysphasia days% of pts with esophageal eosinophils ≤ 6/hpf  Key secondary:% of pts with esophageal eosinophils ≤ 15/hpfEREFSEoE-HSS; mDSD composite score  Ph 2 Atopic Dermatitis POC underway  EoE: Currently enrolling Ph3 study; readout: 2024  Significant reduction in eosinophil count;Wk 16 @ 360mg: 122.6 (baseline) to 25.5 cells/hpfSignificant endoscopic improvement (EOE-EREF);Wk 16 @ 360mg: 9.4 (baseline) to 4.8  Immunology 

   Emerging Immunology Pipeline  96  Phase 1  Phase 2  Phase 3  Marketed  Imm. Tolerance (Anokion)1  MK2 inhibitor  branebrutinib  IL2-CD25  iberdomide  S1PR1 Modulator  deucravacitinib  cendakimab  Anti-CD40  afimetoran (TLR 7/8 inhibitor)  TYK2 inhibitor  1 BMS has an exclusive option to license and/or option to acquire 

 Advancing the pipeline across all therapeutic areas  CardiovascularMavacamten EXPLORER LTE presentationMilvexian TKR Ph 2 positive data  OncologyAdvancement of Opdivo expansion programsRela+Nivo FDC PDUFA dateMarch 19, 2022  HematologyCELMoDs new combination dataBreyanzi TRANSFORM data  Immunologydeucravacitinib filed in U.S. & EU; PDUFA Sept 2022  97 

 deucravacitinib  PsO EU approval PsA Ph3CD & DLE Ph2 (POC)2nd Ph2 in UC IM011-127     PsA Ph3    CD & DLE Ph2 (POC)  cendakimab  EoE Ph3  Zeposia  CD Ph3 Induction/Maintenance  mavacamten  HFpEF Ph2 EMBARK (POC)      Opdivo (+/- Yervoy)  Metastatic: 1L ESCC (CM-648) approvalEarly-stage: Neo-adj lung EFS (CM-816) approval  relatlimab   1L melanoma approvalInitiation Ph3 1Llung (CA224-095)  bempeg  1L melanoma/1L renal/1L bladder  Breyanzi  3L+ LBCL EU approval3L+ CLL (TRANSCEND-CLL) Ph2  98  2022 Key Milestones  Multiple exciting milestones ahead  2023/2024 Key Milestones  Opdivo (+/- Yervoy)  Metastatic:1L CRPC (CM-7DX)1L HCC (CM-9DW)Early-stage:Adj. HCC (CM-9DX)Adj. RCC (CM-914)Peri-adj Lung (CM-77T)Peri-adj MIBC (CM-078)Adj. NSCLC (ANVIL,Co-op group)  Milestones represent data read-outs unless otherwise specifiedTo be expanded to include regulatory milestones pending future registrational successes  Abecma  2L+ MM (KarMMa-2) Ph2 (POC)  CC-92480  4L+ MM Ph1/2  deucravacitinib  PsO U.S. approvalSLE Ph2 (POC)  cendakimab  AD Ph2 (POC)  mavacamten  oHCM approvalSRT (VALOR) Ph3Initiation of Ph3 in nHCM  milvexian  SSP Ph2 (POC)  relatlimab   2L HCC (POC)  bempeg  Neo-adj. CIS-ineligible MIBC  Breyanzi  3L+ FL TRANSCEND Ph2  Abecma  3L+ MM (KarMMa-3) Ph3  CC-93269  Initiation of pivotal trial  iberdomide  Initiation of NDMM Ph3 H2H vs. Rev  CC-92480  Initiation of Ph3 triplet 2L+ MM (w/ Vd, Kd)  Reblozyl  1L MDS (ESA naïve) COMMANDS Ph3MF INDEPENDENCE Ph3  

 Program will reconvene following a short break (10 min) 

 Chris BoernerChief Commercialization Officer  Commercial Opportunities 

     Building blocks of our Continuing Business  deucravacitinib  $3B+  $4B+  Key in-line growth drivers  Key pipeline  $1B+  mavacamten  rela+nivo FDC  Broad New Product Portfolio with significant non-risk adjusted revenue* potential in 2029  + Expansion opportunities across multiple assets  milvexian  BCMA TCE  cendakimab  bempeg  iberdomide  MORAb-202  CC-92480  101  *subject to positive registrational trials and health authority approval 

 In-line growth drivers contribute $8B to $10B growth from 2020-2025  $8.7B 2020 Combined SalesContinued growth opportunity:  102  Drive leadershipin NOAC class  ExpandNOAC class  Increasetreated population   A standard of care across 11 tumors   $9.2B 2020 SalesContinued growth opportunity:  Maintain leadership in Melanoma & RCC  Expand in metastatic disease incl. Lung & GI  Lead evolution inearly-stage disease  Enabled by strong cardiovascular infrastructure 

   Milvexian  Ability to extend leadership in thrombotic diseases with milvexian  103  Building upon history of successful partnerships in CV  Peak global sales:$7.1B (2011)  FY global sales:$9.2B (2020)  Potential to widely span arterial & venous diseasesOpportunity to launch prior to Eliquis LOE in 20281  Potential next-generation anti-thrombotic    1 In the U.S.: Subject to additional appeals and challenges 

     Mavacamten is the first therapeutic candidate to target the heart muscle proteins… with the intent of correcting the abnormal function of the heart.”   Positive feedback from cardiologists on mavacamten  104    Physicians recognize a need for options that address underlying disease vs. treat symptomsDesire by patients & physicians to improve cardiac function and quality of life  Unmet need  The extraordinary data from the EXPLORER pivotal trial confirm mavacamten’s ability to relieve dynamic outflow obstruction, control symptoms and improve quality of life in patients” Dr. Iacopo Olivotto, M.D.Careggi Univ. & lead investigator, EXPLORER-HCM   “  “  Mavacamten perception  Mava targets the underlying pathophysiology of the condition, unlike other treatment methodsRecognition of magnitude of improvement in efficacy measures  Dr. Daniel Jacoby, M.D.Yale School of Medicine  

 $4B+ 2029 NRA sales potential for mavacamten  105  HCM patient population  1.3M patients1  Significant HCM pts with obstructive disease (requiring chronic treatment)  60-70%  >$4B  Opportunity to drive significant penetration with a strong profile based on EXPLORER    + nHCM & additional expansion indications  NRA salesin 2029:  No current treatment that treats underlying conditionNo differentiated competitors on horizonConcentrated prescriber base at launch  Favorable landscape  1U.S./EU5 market prevalenceNRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approval  Opportunity to increase diagnosis rate over time  20-25%  Roughly double  Future  % Pts Symptomatic  60-80%  Today   

 Deucravacitinib’s differentiated profile in psoriasis resonates with dermatologists  106  Based on interview & survey responses for POETYK data in psoriasis:  MOARecognized as novel  EfficacyViewed as compellingComparable to first-generation biologicsSuperior to current oral therapy  SafetyTolerable, with favorable safety profileViewed as differentiated from JAK inhibitorsNo lab monitoring requirement is an important feature  Once-daily dosingPerceived as more convenientthan current SOC 

   Topicals*   Current Orals**  ~1.9M Patients  ~0.4M Patients  Source: Decision Resources Group PsO Report; Symphony Health Claims data 2020 (US); BMS Internal Estimates   Note: Numbers indicate patients on any prescribed treatment (systemic, topical, advanced) in G7 countries *Includes patients treated with Topicals and Phototherapy only**Orals include Otezla, Methotrexate, Cyclosporine and di-methyl fumarate (Mainly in Germany)  Superior efficacy vs OtezlaDurable responses through 1 yearFavorable safety & tolerabilityEase of initiation   Injectables  ~0.4M Patients  Deucravacitinib’s superior profile positioned to become oral of choice in psoriasis & may accelerate switch from topicals      107  Deucravacitinib   

 Significant sales potential in moderate-to-severe psoriasis  108  Large patient population  ~3M patients1  Opportunity to expand systemic oral market  By ~10% e.g., through earlier discontinuation of topicals  Opportunity to establish oral-of-choice  Biologic-like efficacy superior to existing oral SoCFavorable safety and tolerability profiledifferentiated from JAK inhibitorsbetter GI profile compared to existing oral SoC  1Represents combined U.S./EU5 patient prevalence numbers 

 109  $4B+ 2029 NRA opportunity to treat patients with immune-mediated diseases with deucravacitinib  Opportunity to become oral of choice in mod-to-severe PsO  Broaden into Rheumatology, GI & beyond  >$4B NRA salesin 2029            +2M Pts  IBD Mod-Severe(UC/CD)  +1M Pts  +2M Pts  Psoriatic Arthritis  ~3M Pts  Psoriasis (Moderate-to-Severe)  Lupus   NRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approval 

 Reblozyl has $4B+ non risk adjusted sales potential in 2029  Currently approved inTransfusion dependent beta-thal2L RS+ MDS  110  Potential expansion opportunities:1L MDS with COMMANDSMF and others  Opportunity to drive growthin current indications:Increase share in ESA refractory populationIncrease adherenceMore frequent monitoring & earlier switching from ESA failures (NCCN update)  NRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approval 

 Important opportunity to establish Reblozyl in 2L RS+ MDS  111  Patient population  ~8K patients1  Demonstrated repeated periods of transfusion independence  ~50% of patients may not respond to ESAs2; there is potential to treat appropriate patients sooner  ESA retreatment  Increase adherence  Drive adoption  Establish a post-ESA standard of care profile  Address patients earlier in their treatment journey with continued education  1Represents combined U.S./EU5 patient incidence numbers for 2L Lower Risk MDS RS+2NCCN Guidelines define no response as a lack of 1.5 gm/dL rise in hemoglobin or lack of a decrease in RBC transfusion requirement by 6 to 8 weeks of treatment. 

 112  $4B+ non risk adjusted opportunity with Reblozyl in 2029  Expansion into 1L MDS  Establishment of novel MoA  Entry into adjacent disease areas  Notes regarding patient #s: MF & MDS represent combined U.S./EU5 estimates; beta-thal represents U.S. only; noted for each indication in launch year for lead market (e.g. U.S.); patient #s do not include growth of epidemiology over timeNRA = Non-Risk Adjusted Sales, subject to positive registrational trials and health authority approval1 Lower risk MDS patients          +9K Pts  Myelofibrosis  +19K Pts  1L MDS1    Beta-thal  2L RS+ MDS1  ~8K Pts  ~14K Pts  ~6K Pts  >$4B NRA salesin 2029   

 $3B+ Non risk adjusted sales potential in 2029  113    Opportunity to become the oral SOC in UC:Focused on increasing trialists & experienceStep wise approach to growing & broadening access over time  Potential expansion opportunity:Further build presence in IBD with Crohn’s disease  NRA: Non-Risk Adjusted Sales subject to positive registrational trials and health authority approval  Currently approved in:MS: #1 S1P modulator in written RxUC: U.S. launch going well; positive CHMP opinion in EU 

 Significant expansion opportunities for Zeposia in UC  114  Large patient population  ~1.1M patients1   Expand oral market  Drive share of oral market  Establish a new oral SOC, as first S1P modulator with strong profile: Biologic-like efficacy with favorable safety & tolerability profileNo black box warning  Stepwise plan to grow access  Build demandExpand accessConvert to commercial dispense  1Represents combined U.S./EU5 patient diagnosed prevalence numbers; moderate to severe  ~8%  ~20%  Future  Today   Growing oral category over time at the expense of biologics 

 Establish Zeposia as the oral standard of care in UC   115  2021  2022  2023  Establish awareness and acceptance of new MOAEstablish breadth & depth of trialists with differentiated oral risk/benefit profile Elevate patient on-boarding capabilities (e.g., patient services)  Broaden accessAccelerate share uptake by establishing new class as standard of carePatient engagement  Expand access tofirst lineIncrease market growth by reaching uncontrolled patients on conventional therapies Launch integrated strategies reinforcing long-term data 

 Ongoing expansion into UC  Foundation in MS  $3B+ NRA opportunity to expand Zeposia into Crohn’s Disease over time  116  Broaden into CD        +0.9M Pts  +1.1M Pts  Crohn’s disease (Moderate-to-Severe)  Ulcerative Colitis (Moderate-to-Severe)  Multiple Sclerosis  >$3B NRA salesin 2029  0.9M Pts  Note: Patient #s represent combined U.S./EU5 estimates, noted for each indication in launch year for lead market (U.S.); does not include growth of epidemiology over time    NRA: Non-Risk Adjusted Sales subject to positive registrational trials and health authority approval 

 Well positioned to unlock the full potential of Cell Therapy  117      Leading oncology company with a track record of delivering Financial flexibility to invest in current products and next generation technologies  Scale & Experience to realize potential      Favorable Market Dynamics  Strong demand & physician awareness U.S. market primed for outpatientPositive trends in access and reimbursement   Unprecedented outcomes  TRANSFORM 2L LBCL further validates approach and shows the transformative nature of Cell Therapy   BMS is the only company with approved first-in-class or best-in-class products for two distinct targetsAdvancing next generation technologies  Leading Innovation         

 Breyanzi has opportunity to grow into new indications & move up in treatment paradigm  Expand into earlier lines  Enter DLBCL  Broaden into other indications  >$3B NRA salesin 2029  118  ~18K Pts    +22K Pts    +13K Ptsc    +19K Pts    2L CLL  3L+ CLL    2L+ LBCL  3L+ LBCL  3L+ iNHL  +22K Pts      Note: Patient #s represent combined U.S./EU5 estimates, noted for each indication in launch year for lead market (U.S.); does not include growth of epidemiology over time  NRA: Non-Risk Adjusted Sales subject to positive registrational trials and health authority approval 

     $4B+ NRA opportunity with Rela+Nivo FDC, beginning in 2022 with metastatic melanoma  119  Source: Patient Epi from Decision Resources Group; 1 US 2021 patient estimates; includes 1L treated patients & early-stage treatable patients  2 1L Mel US treated patients ~10K, about one-third with IO monos; 3 Early-Stage Mel US treatable patients ~17K; 4 1L NSCLC US treated patients ~106K     Phase 3opportunity inadjuvant melanoma   +  Opdivo + Yervoy  PD-1 monotherapy  BRAF MT  Near-term focus in metastatic melanoma    Near-term launch opportunity with Rela+Nivo FDC:  Additional opportunities:  NSCLC  HCC  CRC  Ongoing data generation can inform future expansion opportunities  Not for Product Promotional Use  NRA: Non-Risk Adjusted Sales subject to positive registrational trials and health authority approval 

 Multiple additional opportunities across therapeutic areas  Key pipeline  $1B+ NRA sales in 2029  + additional expansion opportunities across multiple assets  BCMA TCE  cendakimab  bempeg  iberdomide  MORAb-202  CC-92480  milvexian  Cardiovascular  Immunology  Oncology  Hematology  120  NRA: Non-Risk Adjusted Sales subject to positive registrational trials and health authority approval 

 David ElkinsChief Financial Officer  Financial Overview   

 Confidence in our future  122  Strong innovation engine with deep scientific expertise to replenish the portfolioIndustry leading commercial capabilities to maximize growth by reaching more patients with unmet medical needs Strong execution provides confidence to deliver the full potential of our commercial brands and future pipeline & reinforces ability to navigate upcoming LOEsFinancial strength and flexibility to further strengthen the portfolio and provide healthy return of capital to shareholders   

 Opdivo (+/- Yervoy)  U.S./EU expected approvals:1L RCC (9ER) , 1L GC (649, O+Chemo), adj Eso (577) adj MIBC (274)     1L Esophageal (CM-648)    Opdivo return to annual growth  Relatlimab   1L Melanoma w/ Opdivo Ph3  Breyanzi  3L+ DLBCL U.S. / EU approval3    2L TE and TNE DLBCL     3L+ CLL3   Abecma  4L+ MM U.S.1 / EU approval  Iberdomide + dex  4L+ MM Ph 1b/2a  Deucravacitinib  PsO (2nd study) Ph3 & U.S. filing    UC Ph2 (POC)  Zeposia  UC U.S. / EU approval  Cendakimab  Initiation of Ph3  Factor XIa inh.  Total Knee Replacement VTEp Ph2 (POC)  Mavacamten  oHCM U.S. filing & approval2  Opdivo (+/- Yervoy)  Metastatic1L HCC (CM-9DW)    AdjuvantNeo-adj Lung EFS (CM-816)Peri-adj Lung (CM-77T)  Bempeg  1L melanoma3 & 1L renal   Breyanzi  3L+ Follicular lymphoma  Abecma  3L+ MM (KarMMa-3) Ph3    2L+ MM (KarMMa-2) POC  CC-92480  4L+ MM Ph1/2  CC-93269 (TCE)  Initiation of pivotal trial  Deucravacitinib  PsO U.S./EU approval    CD & Lupus Ph2 (POC)  Zeposia  CD Ph3  Factor XIa inh.  Secondary Stroke Prevention Ph2 (POC)  Reblozyl  1L MDS (ESA naïve) COMMANDS Ph3  Ph 1/2 Pipeline  >20 POC decisions  123  2021 Key Milestones  BMS continues to execute against our commitments    2020-2025:Low to mid-single digit revenue CAGR*Low double-digit revenue CAGR for Continuing business*Operating margins low to mid 40%s**~$3B of synergies by end of 2022$45B - $50B of free-cash flow 2021-2023**  Financial Expectations  2022/2023 Key Milestones  To be expanded to include regulatory milestones pending future registrational successes  Not for Product Promotional Use  On track based on 2021 guidance  1Approved after 4 prior lines of therapy2 PDUFA January 28, 20223 Expected in 2022  *At constant exchange rates – Non-GAAP: there is no reliable or reasonable estimable comparable GAAP metric for this Non-GAAP forward-looking information; **Non-GAAP: there is no reliable or reasonable estimable comparable GAAP metric for this forward-looking information   

 Strong execution reinforces our confidence in our financial targets   124  Strong Financial Foundation and Portfolio Positioned for Growth  Operating Margins in low to mid-40s**~$3B of Synergies by end of 2022$45 – 50B of Free Cash Flow from 2021-2023  Low double-digit Revenue CAGR for Continuing Business 2020-2025*$25B+ NRA Revenue Potential in 2029 for Launch Brands  Low to mid-single digit Revenue CAGR 2020–2025*Continuing Business ~90%of Total Revenue by 2025Launch Portfolio ~30% of Continuing Business by 2025  Total Company Growth & Revenue Profile  Revenue Replacement Power  Financial Strength  *at constant exchange rates - There is no reliable or reasonable estimable comparable GAAP metric for this forward-looking information **Non-GAAP - There is no reliable or reasonable estimable comparable GAAP metric for this forward-looking informationNRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approval   

 Continued In-Line performance and New Product Portfolio more than offsets impact from near-term LOEs  LOE Brands = Revlimid, Pomalyst, Sprycel, and Abraxane  *At constant exchange rates – Non-GAAP. There is no reliable or reasonable estimable comparable GAAP metric for this forward-looking information    ($12B–$14B)  +$8B–$10B  +$10B–$13B  2020 Revenues  LOE Brands  In-Line Brands  Primarily I-O & Eliquis  2025 Revenues  New Product Portfolio  Growth 2020-2025Low to mid-single digit revenue CAGR*    Continuing Business  2022: Expect revenue and Non-GAAP EPS growthBy 2025, expect $10-$13B risk-adjusted opportunity from new product portfolio  125 

     We expect New Product Portfolio to deliver $10B-$13B of risk-adjusted revenue in 2025  126  AbecmaOnuregInrebicrela+nivo FDC  Significantly de-risked portfolio: 9 new products: 6 approved, 3 filedIncreased confidence in expansion opportunitiesZeposia launch in UCBreyanzi 2L+ LBCL deucravacitinib PsA Ph3 underway   2025: $10B-$13B Risk-adjusted sales  Reblozyl 2L MDS  Onureg AML  Zeposia MS  Breyanzi 3L+ LBCL  Zeposia UC  Abecma 5L+  mavacamten oHCM  rela+nivo 1L Mel FDC  deucravacitinib PsO  Breyanzi 2L LBCL  Zeposia CD  Reblozyl 1L MDS  Abecma 3-5L  Breyanzi 3L+CLL  Breyanzi 3L+ iNHL  2020  2021  2022  2023  2024  2025  Other  deucrava  Zeposia  Breyanzi  Reblozyl  mavacamten   

 Path to maintaining Operating Margins  127  *Non-GAAP - There is no reliable or reasonable estimable comparable GAAP metric for this forward-looking information    Low to mid-single digit Total Company Revenue CAGR from 2020 - 2025  Gross Margin decline tempered by growth in high-margin launch brands and I-O    Operating expenses as % sales improves as revenue growth outpaces expense growth  Operating Margins to remain in low to mid 40s through 2025*   

   Strong cash flow provides for tremendous financial flexibility  128  $45B - $50Bin free cash flow 2021-2023  *Future dividend payouts subject to board authorization  Prioritizing Business Development to replenish and diversify the portfolio to drive long-term growth    Strengthening the Balance Sheet to enable greater strategic and financial flexibility     Returning cash to shareholders  Continue to execute small & mid-sized bolt-on opportunities   Reduction of debtMaintain strong investment-grade credit rating  Continued dividend growth*Opportunistic share repurchase 

 Business Development remains a top priority to complement the portfolio for long-term growth  129  Deals over the last 18 months  A further diversified pipeline  Oncology  Hematology   Immunology   Cardiovascular   Neurology  Financial Discipline  Significant capacity for business development – strong rating & FCF generation Create value by leveraging leading capabilities in most strategic therapeutic areas  Will continue to execute BD in leading scientific areas of high unmet medical need  

 Well positioned for future growth   130  Business continues to execute well against our financial and pipeline commitmentsStrong innovation engine for continued growth into the second half of the decadeConfident in our ability to address future LOEs   Financial strength and flexibility to further strengthen the portfolio and provide healthy return of capital to shareholders  New productsexpected to deliver $10B-$13B risk-adjusted revenue in 2025  Continued growthof new product portfolio $25B+ non-risk adjusted revenue* in 2029  Pipeline & business development targets focused in therapeutic areas with significant commercial potential         *Non-Risk Adjusted revenue subject to positive registrational trials and health authority approval 

 Giovanni CaforioBoard Chair and Chief Executive Officer 

 Cardiovascular  Opportunity for franchise durability and growth across all four key therapeutic areas  Oncology  Hematology  Immunology  132  New Products      Robust early-stage pipeline with 50+ assets in development  deucravacitinib*  rela+nivo FDC*  bempeg  iberdomide  milvexian  cendakimab  Inline Brands  Next Wave  mavacamten*  MORAb-202 (FRa ADC)  CC-92480  BCMA TCE (CC-93269)  * Subject to positive registrational trials & regulatory approval  

 deucravacitinib  PsO EU approval PsA Ph3CD & DLE Ph2 (POC)2nd Ph2 in UC IM011-127     PsA Ph3    CD & DLE Ph2 (POC)  cendakimab  EoE Ph3  Zeposia  CD Ph3 Induction/Maintenance  mavacamten  HFpEF Ph2 EMBARK (POC)      Opdivo (+/- Yervoy)  Metastatic: 1L ESCC (CM-648) approvalEarly-stage: Neo-adj lung EFS (CM-816) approval  relatlimab   1L melanoma approvalInitiation Ph3 1Llung (CA224-095)  bempeg  1L melanoma/1L renal/1L bladder  Breyanzi  3L+ LBCL EU approval3L+ CLL (TRANSCEND-CLL) Ph2  133  2022 Key Milestones  Multiple exciting milestones ahead  2023/2024 Key Milestones  Opdivo (+/- Yervoy)  Metastatic:1L CRPC (CM-7DX)1L HCC (CM-9DW)Early-stage:Adj. HCC (CM-9DX)Adj. RCC (CM-914)Peri-adj Lung (CM-77T)Peri-adj MIBC (CM-078)Adj. NSCLC (ANVIL,Co-op group)  Milestones represent data read-outs unless otherwise specifiedTo be expanded to include regulatory milestones pending future registrational successes  Abecma  2L+ MM (KarMMa-2) Ph2 (POC)  CC-92480  4L+ MM Ph1/2  deucravacitinib  PsO U.S. approvalSLE Ph2 (POC)  cendakimab  AD Ph2 (POC)  mavacamten  oHCM approvalSRT (VALOR) Ph3Initiation of Ph3 in nHCM  milvexian  SSP Ph2 (POC)  relatlimab   2L HCC (POC)  bempeg  Neo-adj. CIS-ineligible MIBC  Breyanzi  3L+ FL TRANSCEND Ph2  Abecma  3L+ MM (KarMMa-3) Ph3  CC-93269  Initiation of pivotal trial  iberdomide  Initiation of NDMM Ph3 H2H vs. Rev  CC-92480  Initiation of Ph3 triplet 2L+ MM (w/ Vd, Kd)  Reblozyl  1L MDS (ESA naïve) COMMANDS Ph3MF INDEPENDENCE Ph3  

   New Product Portfolio and pipeline provide multiple pathways to growth from 2025 to 2029    New product portfolio and pipeline products will continue to provide revenue replacement power, offsetting Eliquis and I-O LOEs        Additional optionality from disciplined Business Development  Delivery of late-stage pipelineCombination of new products & high-value expansion opportunities:Reblozyl LCMdeucravacitinib LCMmavacamten LCMrelatlimab LCMmilvexianiberdomide   2025 Revenues  LOE Brands  2029 Revenues  Additional growth from New Product Portfolio  Advancing robust pipeline  Diverse, growing New Product Portfolio        Growth 2025-2029  134 

 Well positioned for the near-term and long-term  135  Confident in our ability to navigate upcoming LOEs  Strong position to grow and renew our business  Strong cash flow and balance sheet strength support ability to execute disciplined business development  Significant growth potential from new product portfolio  Exciting pipeline with differentiated firstand/or best-in-class assets 

 Investor Meeting Q&A  136  Giovanni CaforioBoard Chair andChief Executive Officer  Chris BoernerChief Commercialization Officer  David ElkinsChief Financial Officer  Samit HirawatChief Medical Officer,Global Drug Development  Rupert VesseyPresident, Research & Early Development   

     Appendix 

   Hematology  Fibrosis  HSP47  LPA1 Antagonist  Immunology  Oncology  Data as of November 16, 2021  Anti-Fucosyl GM1  Anti-OX40  TIGIT Bispecific  Anti-NKG2A  Anti-SIRPα1  AR LDD  Anti-CTLA-4 NF  Anti-CCR8  Anti-CTLA-4 Probody  BCMA TCE  CD3xPSCA(GEMoaB)2  IL-12 Fc  Anti-IL-8  Anti-TIGIT  BET Inhibitor(BMS-986158)  CD19 NEX T  BCMA ADC  BCMA CAR T(bb21217)  TGFβ Inhibitor  LSD1 Inhibitor1  iberdomide  1 In development for solid tumors and hematology2 BMS has an exclusive option to license and/or option to acquire  iberdomide  MK2 Inhibitor  Anti-CD40  IL2-CD25  Imm. Tolerance (Anokion)2  cendakimab  branebrutinib  deucravacitinib  Cardiovascular  FA-Relaxin  FXIa Inhibitor  139  Phase 1  Phase 2  Phase 3  A/I CELMoD(CC-92480)  A/I CELMoD(CC-99282)  GSPT1 CELMoD(CC-90009)  BET Inhibitor1(CC-90010)  CD33 NKE  CD47xCD20  Neuroscience  Anti-Tau(Prothena)2  AHR Antagonist(Ikena)2  S1PR1Modulator  afimetoran(TLR 7/8 Inhibitor)  BET Inhibitor1(CC-95775)  NME  FPR-2 Agonist  Active Clinical Development Portfolio  STING Agonist  danicamtiv  BCMA NEX T  motolimod  Cardiac Myosin Inhibitor  milvexian(FXIa Inhibitor)  mavacamten  TYK2 Inhibitor  GPRC5D CAR T  COVID-19  SARS-CoV-2 mAb Duo  Anti-CTLA-4 NF-Probody  CK1α CELMoD  ROMK Inhibitor  BTK Inhibitor  BCMA NKE  ROR1 CAR T  Anti-TIM3  farletuzumab - eribulin ADC  FAAH/MGLL Dual Inhibitor  relatlimab1  bempegal-desleukin  linrodostat  subcutaneous nivolumab  eIF2b Activator  Marketed 

 140  Abbreviations  ACC  American College of Cardiology  DLBCL  Diffuse Large B-Cell Lymphoma  MM  Multiple Myeloma  RR  Relapsed Refractory    ACR  American College of Rheumatology  DLE  Discoid Lupus Erythematosus  MR  Minimal Response  RS  Ring Sideroblasts    ACS  Acute Coronary Syndrome  EADV  European Academy of Dermatology and Venereology  MS  Multiple Sclerosis  SAE  Serious Adverse Event    AD  Atopic Dermatitis  EFS  Event Free Survival  MSI-H  High Microsatellite Instability  SC  Subcutaneous    ADC  Antibody Drug Conjugate  EoE  Eosinophilic Esophagitis  MTD  Maximum Tolerated Dose  sCR  Stringent Complete Response    Adj  Adjuvant  ESA  Erythropoietin Stimulating Agents  NE  Not Evaluable  SCT  Stem Cell Transplant    AE  Adverse Event  ESCC  Esophageal Squamous Cell Carcinoma  nHCM  Non-Obstructive Hypertrophic Cardiomyopathy  SD  Stable Disease    AFIB  Atrial Fibrillation  FDC  Fixed Dose Combination  NKE  Natural Killer Cell Engager  SLE  Systemic Lupus Erythematosus    AHA  American Heart Association  FL  Follicular Lymphoma  NRA  Non-Risk Adjusted  SoC  Standard of Care    AML  Acute Myeloid Leukemia   GAAP  Generally Accepted Accounting Principles  NRI  Nonresponder Imputation  sPGA  Static Physicians Global Assessment    AR-LDD  Androgen Receptor Ligand Degrader  GC  Gastric Cancer  NSCLC  Non-Small Cell Lung Cancer  SRT  Septal Reduction Therapy    ASH  American Society of Hematology  HCC  Hepatocellular Carcinoma  NSQ  Nonsquamous  SSP  Secondary Stroke Prevention    A-Thal  Alpha Thalassemia  HFpEF  Heart Failure w/ Preserved Ejection Fraction   NTD  Non-Transfusion Dependent  TCE  T-Cell Engager    BCMA  B-Cell Maturation Antigen  IBD  Inflammatory Bowel Disease  NYHA  New York Health Association  TD  Transfusion Dependent    BID  Twice a Day  IMiD  Immunomodulatory Drugs  OAC  Oral Anticoagulant  TE   Transplant Eligible    B-Thal  Beta Thalassemia  IND  Investigational New Drug  oHCM  Obstructive Hypertrophic Cardiomyopathy  TEAE  Treatment Emergent Adverse Events    CAD  Coronary Artery Disease  iNHL  Indolent Non-Hodgkin's Lymphoma  ORR  Overall Response Rate  TKR  Total Knee Replacement    CAGR  Compound Annual Growth Rate  I-O  Immuno-Oncology  PAD  Peripheral Artery Disease  TNE  Transplant Non-Eligible    CAR T  Chimeric Antigen Receptor Therapy  ITT  Intent to Treat  PASI  Psoriasis Area and Severity Index  TNFi  Tumor Necrosis Factor Inhibitor    CBR  Clinical Benefit Rate  LBCL  Large B-Cell Lymphoma  PD  Progressive Disease  UC  Ulcerative Colitis    CD  Crohn’s Disease  LOE  Loss of Exclusivity  PDUFA  Prescription Drug User Fee Act  VGPR  Very Good Partial Response    CELMoD  Cereblon E3 Ligase Modulator  LVOT  Left Ventricular Outflow Tract  POC  Proof of Concept  VTEp  Venous Thromboembolism Prevention    CLL  Chronic Lymphocytic Leukemia  mCRPC  Metastatic Castration-Resistant Prostate Cancer   PR  Partial Response        CR  Complete Response  MDS  Myelodysplastic Syndrome   PsA  Psoriatic Arthritis        CRC  Colorectal Cancer  mDSD  modified Daily Symptom Diary  PsO  Psoriasis        CRS  Cytokine Release Syndrome  Mel  Melanoma  QD  Once Daily        CTA  Clinical Trial Application  MF  Myelofibrosis  RCC  Renal Cell Carcinoma        DCR  Disease Control Rate  MIUC  Muscle Invasive Urothelial Cancer  RP2D  Recommended Phase 2 Dose